---
figid: PMC6914774__41392_2019_99_Fig1_HTML
figtitle: The emerging treatment landscape of targeted therapy in non-small-cell lung
  cancer
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC6914774
filename: 41392_2019_99_Fig1_HTML.jpg
figlink: /pmc/articles/PMC6914774/figure/Fig1/
number: F1
caption: There are several abnormal signaling and cell physiology-related pathways
  in lung cancer. Drugs targeting these abnormal pathways are depicted schematically.
  These drugs include agents specifically inhibiting components of the EGFR pathway
  and other family members and/or members of the VEGFR pathways. Other agents in development
  include inhibitors of the PI3K/AKT/mTOR pathway, the RAS/BRAF/MAPK pathway, and
  the JAK–STAT pathway.
papertitle: The emerging treatment landscape of targeted therapy in non-small-cell
  lung cancer.
reftext: Min Yuan, et al. Signal Transduct Target Ther. 2019;4:61.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9490281
figid_alias: PMC6914774__F1
figtype: Figure
redirect_from: /figures/PMC6914774__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6914774__41392_2019_99_Fig1_HTML.html
  '@type': Dataset
  description: There are several abnormal signaling and cell physiology-related pathways
    in lung cancer. Drugs targeting these abnormal pathways are depicted schematically.
    These drugs include agents specifically inhibiting components of the EGFR pathway
    and other family members and/or members of the VEGFR pathways. Other agents in
    development include inhibitors of the PI3K/AKT/mTOR pathway, the RAS/BRAF/MAPK
    pathway, and the JAK–STAT pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - mir-133
  - mir-7
  - mir-1
  - mir-124
  - hop
  - bsk
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Ras85D
  - Pten
  - Akt
  - Mtor
  - Tor
  - MKP-4
  - p38b
  - rl
  - tt
  - EGF
  - MIR21
  - MIR34A
  - MIR30B
  - LILRB1
  - FSD1
  - FSD1L
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - MIR126
  - MIR203A
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - MIR23A
  - BRAF
  - MIR410
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - MIR202
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AMBP
  - gefitinib
  - erlotinib
  - Ruxolitinib
  - seluetinib
  - trametinib
  - LY294002
  - AP23573
  - Sorafenib
  - Temsirolimus
---
